Evaluating the Use of Glucocorticoids Among Belimumab‐Treated Patients With Systemic Lupus Erythematosus in Real‐World Settings Using the Rheumatology Informatics System for Effectiveness Registry

OBJECTIVE: Glucocorticoids are part of standard therapy for systemic lupus erythematosus (SLE), despite adverse effects associated with long‐term treatment. Belimumab improved clinical manifestations of SLE and reduced glucocorticoid doses in clinical trials and clinical practice; however, associati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammam, Nevin, Evans, Michael, Bell, Christopher F., Gairy, Kerry, Yazdany, Jinoos, Schmajuk, Gabriela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2022
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555183/
https://www.ncbi.nlm.nih.gov/pubmed/35872599
http://dx.doi.org/10.1002/acr2.11482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555183/
https://www.ncbi.nlm.nih.gov/pubmed/35872599
http://dx.doi.org/10.1002/acr2.11482

Ejemplares similares